Eli Lilly and Company
Business Model Analysis
How Eli Lilly Makes Money
Annual Revenue: $65.2B
Eli Lilly generates revenue primarily through Pharmaceuticals, with roughly $65.2B in annual revenue.
Core Growth Engine: Lilly's growth strategy has three parts: expand incretin supply and indications, add oral and next-generation obesity medicines, and diversify through oncology, immunology, neuroscience and genetic medicine. Foundayo (or...
Revenue Model & Pricing
Lilly makes money by discovering, developing, manufacturing and selling patent-protected prescription medicines. Revenue comes mainly from product sales to wholesalers, pharmacies and health systems, with net prices set through negotiations with insurers, pharmacy benefit managers and governments; collaboration and royalty income adds a smaller share. Cardiometabolic medicines dominate: Mounjaro ($22.97 billion) and Zepbound ($13.54 billion) together produced about 56% of 2025 revenue. Lilly also sells directly to self-pay patients through LillyDirect, including Zepbound vials and Foundayo tablets, which reduces reliance on traditional pharmacy benefit channels for obesity care.
Core Revenue Streams
Branded Prescription Medicines
PrimarySales of patent-protected medicines through wholesalers, pharmacies, health systems, and international channels.
Collaborations and Licensing
SupportingMilestones, royalties, and collaboration economics connected to research, development, and commercialization partnerships.
Growth Strategy
Lilly's growth strategy has three parts: expand incretin supply and indications, add oral and next-generation obesity medicines, and diversify through oncology, immunology, neuroscience and genetic medicine. Foundayo (orforglipron) was approved by the FDA on April 1, 2026 and launched through LillyDirect, telehealth and U.S. retail pharmacies. Retatrutide, a GIP/GLP-1/glucagon triple agonist, is in Phase 3. Lilly continues to build U.S. and European manufacturing capacity and uses acquisitions to add pipeline assets.
How Eli Lilly Makes Money: FAQ
How does Eli Lilly generate revenue across its pharmaceutical portfolio?
Eli Lilly generated revenue of $65.2 billion in 2025 (up 45% from $45.0 billion in 2024) through the discovery, clinical development, manufacturing, and global wholesale distribution of patented prescription therapeutics across four core therapeutic areas: Diabetes and Metabolic Health, Oncology, Immunology, and Neuroscience.
What are Eli Lilly's top-selling blockbuster drugs by revenue contribution?
Lilly's revenue is anchored by: Mounjaro & Zepbound (tirzepatide for diabetes and obesity, driving tens of billions in sales), Trulicity (dulaglutide for diabetes), Verzenio (abemaciclib for breast cancer), Taltz (ixekizumab for psoriasis/arthritis), Jardiance (empagliflozin), and Humalog (insulin).
What is the economic model of dual GIP/GLP-1 incretin therapeutics like tirzepatide?
By simultaneously activating both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) hormone pathways, tirzepatide delivers superior metabolic control and appetite suppression, capturing large commercial demand across diabetes, obesity, cardiovascular risk, and sleep apnea.
How does Eli Lilly invest in Research and Development (R&D)?
Eli Lilly is one of the world's most R&D-intensive corporations, spending $13.3 billion on research and development in 2025 (about 20% of revenue) on discovering novel molecular entities, genetic medicines, radiopharmaceuticals, and conducting global Phase 1 to 3 clinical trials.
What is Eli Lilly's domestic manufacturing expansion plan?
To satisfy global demand for tirzepatide, Lilly committed over $18 billion to construct large state-of-the-art sterile injectable manufacturing campuses in Lebanon (Indiana), Research Triangle Park (North Carolina), Concord (NC), Ireland, and Alzey (Germany).
What role do wholesale distributors and pharmacy benefit managers (PBMs) play in Lilly's distribution?
Lilly sells prescription medications primarily through major pharmaceutical wholesalers (McKesson, AmerisourceBergen / Cencora, Cardinal Health), negotiating commercial formulary placement and statutory rebates with pharmacy benefit managers (PBMs).
What is orforglipron (Foundayo)?
Orforglipron is Lilly's once-daily oral small-molecule GLP-1 receptor agonist, approved by the FDA as Foundayo on April 1, 2026 for chronic weight management. As a pill that needs no injection or food timing, it is easier to manufacture and distribute than peptide injectables.
How does Eli Lilly protect intellectual property through patent exclusivity?
Lilly secures multi-decade global composition-of-matter patents, formulation patents, and regulatory exclusivity periods (typically 10 to 14 years from commercial launch), generating high gross margins that fund subsequent generations of drug research.
How does Eli Lilly make money?
They operate a classic, massive pharmaceutical model. They spend billions on R&D to discover novel molecules. Once approved by the FDA, they secure a massive 20-year patent monopoly, allowing them to charge astronomical prices for blockbuster drugs like Trulicity (diabetes) and Zepbound (obesity).
Related Monetization Mechanics
Compare revenue streams, unit economics, and business models
Explore Eli Lilly
Core profile pages, founders and related research hubs for this company.